EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Ceftazidime/avibactam for the treatment of bloodstream infection due to carbapenemase-producing Enterobacterales in onco-haematologic neutropenic patients (the TARZAN study)

Enric Sastre-Escolà, Fotinie Ntziora, Matteo Chiurlo, Pilar Martín-Dávila, Malgorzata Mikulska iD, Adaia Albasanz-Puig iD, Marina Machado iD, Andrea Gutiérrez-Villanueva, Ignacio Márquez-Gómez, Oriol Gasch-Blasi, Nikolaos V Sipsas iD, Chiara Oltolini und 9 weitere

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf120 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Enric Sastre-Escolà und 20 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospital…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacteremia, Carbapenem-Resistant Enterobacteriaceae, Ceftazidime. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Pfizer International, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess the clinical features, antibiotic therapy and outcomes of carbapenemase-producing Enterobacterales bloodstream infection (CPE-BSI) in neutropenic patients with haematological malignancies treated with ceftazidime/avibactam.

Methods

We conducted a multicentre, international, retrospective, descriptive study of CPE-BSI episodes in neutropenic onco-haematological patients treated with ceftazidime/avibactam as empirical and/or targeted therapy (2017–2022).

Results

Of 54 episodes of CPE-BSI in haematological patients with neutropenia, more than half presented acute myeloid leukaemia (32, 59.5%). Klebsiella pneumoniae was the most frequently isolated pathogen (79.5%) and KPC the most prevalent carbapenemase (52%). The source of BSI was mainly endogenous (57.5%). Up to 11% presented with septic shock. Initial empirical antibiotic therapy was inadequate in 47% of cases, particularly monotherapy with meropenem or piperacillin/tazobactam. Ceftazidime/avibactam was administered empirically in 30% of patients and targeted in all episodes, mainly in combination with aminoglycosides, colistin or tigecycline. Nephrotoxicity occurred in 15% of patients, being attributed to aminoglycosides or colistin. Intensive care unit admission was required in 20% of cases. All-cause 7-day and 30-day case-fatality rates were 11% and 24%, respectively. Multivariate analysis showed that septic shock at BSI onset was an independent risk factor for 30-day mortality.

Conclusions

Ceftazidime/avibactam proved to be safe and efficacious for the treatment of CPE-BSI in this extremely high-risk population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsBacteremiaCarbapenem-Resistant EnterobacteriaceaeCeftazidimeEnterobacteriaceae InfectionsHematologic NeoplasmsNeutropeniaAdultAgedFemaleHumansMaleMiddle AgedYoung AdultAzabicyclo CompoundsBacterial Proteinsbeta-LactamasesDrug CombinationsKlebsiella pneumoniaeMicrobial Sensitivity TestsRetrospective StudiesTreatment Outcome

Substanzen

Anti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial Proteinsbeta-LactamasescarbapenemaseCeftazidimeDrug Combinations

Autor:innen und Institutionen

  • Infectious Diseases Department, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
  • Clinic of Infectious Diseases, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Infectious Diseases Department, Hospital Ramón y Cajal, Madrid, Spain.
  • Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

ORCID-Profile: Malgorzata Mikulska, Adaia Albasanz-Puig, Marina Machado, Nikolaos V Sipsas, Jesús Fortún, Ana Fernández-Cruz, Jordi Carratalà

Förderung

  • Pfizer International
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas
  • Instituto de Salud Carlos III
  • Instituto de Salud Carlos III, Madrid, Spain

Zitieren

APA

Sastre-Escolà, E., Ntziora, F., Chiurlo, M., Martín-Dávila, P., Mikulska, M., Albasanz-Puig, A., Machado, M., Gutiérrez-Villanueva, A., Márquez-Gómez, I., Gasch-Blasi, O., Sipsas, N. V., Oltolini, C., Fortún, J., Ruiz-Camps, I., Fernández-Cruz, A., Peña, M., Laporte-Amargos, J., Bergas, A., Badia-Tejero, A. M., …, & Gudiol, C. (2025). Ceftazidime/avibactam for the treatment of bloodstream infection due to carbapenemase-producing Enterobacterales in onco-haematologic neutropenic patients (the TARZAN study). Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf120

Vancouver

Sastre-Escolà E, Ntziora F, Chiurlo M, Martín-Dávila P, Mikulska M, Albasanz-Puig A, et al. Ceftazidime/avibactam for the treatment of bloodstream infection due to carbapenemase-producing Enterobacterales in onco-haematologic neutropenic patients (the TARZAN study). Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf120

BibTeX
@article{SastreEscol2025,
  author = {Sastre-Escolà, Enric and Ntziora, Fotinie and Chiurlo, Matteo and Martín-Dávila, Pilar and Mikulska, Malgorzata and Albasanz-Puig, Adaia and Machado, Marina and Gutiérrez-Villanueva, Andrea and Márquez-Gómez, Ignacio and Gasch-Blasi, Oriol and Sipsas, Nikolaos V and Oltolini, Chiara and Fortún, Jesús and Ruiz-Camps, Isabel and Fernández-Cruz, Ana and Peña, Marta and Laporte-Amargos, Julia and Bergas, Alba and Badia-Tejero, Ana Maria and Carratalà, Jordi and Gudiol, Carlota},
  title = {Ceftazidime/avibactam for the treatment of bloodstream infection due to carbapenemase-producing Enterobacterales in onco-haematologic neutropenic patients (the TARZAN study)},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf120}
}
Kostenlos starten →